Company Overview

Update
Headquarters:
San Diego, CA
IPO:
Went Public on May 21, 2013
Stock:
NASDAQ:ACAD
Categories:
Biotechnology

ACADIA Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.

Description

Update

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson’s disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer’s disease psychosis, for which it is initiating a Phase II feasibility study.

Current Team (5)

Update

Board Members and Advisors (11)

Update

Funding Rounds (2) - $101.40M

Update

Investors (2)

Update

Offices/Locations (1)

Update
  • Office

    3911 Sorrento Valley Blvd

    San Diego, CA 92121

    USA